И уште еден мит замина за вакцините. Нова студија од Холандија, практично ранливите категории не прават никакви или многу малце антитела.
Страшно е ова како се се распаѓа околу вакцините откако Филипче и Заев зедоа да ги фалат.
The study:
https://www.zonmw.nl/nl/over-zonmw/coronavirus/onderzoek-naar-corona-en-covid-19/vaccinatie/
Hundreds of thousands of people in the Netherlands whose immune systems do not work properly do not benefit, or benefit only slightly, from vaccinations against SARS-CoV-2. Part of this large group does not produce antibodies and immune cells. The rest produce too little of them. Other vaccinations cause similar problems in these patients.
In some patients the vaccinations work better than expected. This applies, for example, to dialysis patients and to patients with certain congenital disorders of the immune system. They produce about as many antibodies as healthy people.
People who do not respond well to the vaccines are patients who take immunosuppressive drugs, transplant patients, (blood) cancer patients and people with congenital disorders of the immune system. People with HIV and people with Down syndrome are also at risk.
Immune-suppressing drugs are taken, for example, by patients with autoimmune diseases such as rheumatoid arthritis. The extent to which the effect of vaccinations is diminished by the immunosuppressive drugs depends on the dosage, on any use of combinations of drugs and on the severity of the condition. In total, 820,000 Dutch people took an immune check in 2020, according to the Foundation for Pharmaceutical Statistics. In the first six months of 2021, 520,000 people did so. Since the beginning of this year, eight studies have been running in the Netherlands on different subgroups of patients who suffer from impaired immunity. ZonMw, the main financier of medical-scientific research, has allocated 15.5 million for the studies.
In a webinar organized by ZonMw today, the first results of four studies were announced. These have not yet been published or peer reviewed.
Collaboration
The studies are being conducted in close collaboration between the Dutch UMCs. RIVM and ZonMw have ensured that the studies use a standardized method to measure the immune response of the participants, so that the results are mutually comparable.
Severe kidney disease patients have a three to five times higher risk of dying from covid-19 than average. The study on vaccination of kidney patients yielded relatively favorable outcomes for patients with renal failure and dialysis patients. Over 80 percent of those patients produced sufficient antibodies after complete vaccination.
Of those who have undergone kidney transplantation, two-thirds did not respond or responded inadequately to vaccination. They do not build up protection, or not enough.
Survivors
In patients who have undergone lung transplantation, the picture is more complicated. If those contract covid-19, their transplanted lungs are affected.
Patients who have undergone lung transplantation and have survived covid-19 build up a good defence against the virus after vaccination. One vaccine is then sufficient as a booster for the natural defenses. Patients on the waiting list for a lung transplant also benefit from vaccination.
The situation is very different for transplanted patients who have not yet received covid-19. Of the more than 100 patients who took part in the study, only 13 percent produced sufficient antibodies.
Blood cancer
Every year there are about ten thousand diagnoses with a form of blood cancer or lymphoma in the Netherlands. All those patients have various disorders of the immune system. For the study, 850 patients were selected with 17 different forms of blood or lymph node cancer and all at risk of severe course of covid-19.
In all patients, the functioning of the immune system is disturbed. This may be because they are undergoing chemotherapy, immunotherapy or cell therapy or because their tumor is paralyzing the immune system. There are also patients who are receiving immunosuppressive drugs or whose immune system is recovering after a stem cell transplant.
According to guidelines, patients in this group should not receive vaccination during treatment for their hematological condition. During the study, the patients did get vaccinated. Some of them reacted better than expected and produced sufficient antibodies, while others did not.
Variation
A similar difference in reactions to vaccination occurs in patients with congenital disorders of the immune system. While some do not produce antibodies at all, others do and to a sufficient degree.
The patients with the most severe forms of immunodeficiency - the lack of certain substances crucial to the immune system - did not benefit from vaccination.
A third or possibly even a fourth shot could improve protection for some of the people with immune problems. Further research is being done into this. For another group of patients, even third or even fourth shots will not elicit protection, the researchers expect.
Initial results studies on corona vaccine efficacy in vulnerable groups
Posted on August 17, 2021 The UMCG is conducting research into the effect of COVID-19 vaccines in kidney patients, lung transplant patients and patients with cancer. On Tuesday, August 17, the first two studies presented their results. Vaccinations do not work sufficiently in several patient groups.
Family in lockdown
During an information session for interested media, a kidney transplant patient explained the impact of corona on her life. She received a kidney transplant in 2007 and takes medication to ensure that her immune system does not reject the new kidney. For patients like her, the corona virus is especially dangerous: she can become seriously ill from the virus and the risk of death for her is considerably greater than for others.
She and her family have been in lockdown since the beginning of the pandemic. For example, her son is not going to school. Although she says she is used to it, it is clear that the situation is taking its toll on her and her family. And there are many like this patient: an estimated 500,000 people in the Netherlands with weakened immune systems are at extra risk during the pandemic and are therefore severely restricted in what they can and cannot do.
Importance of an effective vaccine
A vaccine that works well and is safe is especially important for these vulnerable people. However, the currently available vaccines have mainly been studied in relatively healthy adults. Specific risk groups are not included in these studies, or only to a very limited extent. As a result, there is insufficient knowledge about the immune response of the vaccine in patients who are known to have a less well-functioning immune system, as a result of a congenital disorder, from medication after a transplant or from chemotherapy or immunotherapy for cancer.
From ZonMw, eight studies have been started into the effect of COVID-19 vaccines in vulnerable groups. Three of these are coordinated in the UMCG. These are studies into the effect of COVID-19 vaccines in kidney patients, lung transplant patients and patients with cancer. The first two presented their first results on Tuesday, August 17.
Effectiveness in lung transplant patients
Corona vaccines are safe for lung transplant patients, but in a good proportion of patients who have undergone lung transplantation, the corona vaccination is not or hardly effective, because virtually no antibodies are produced. This is evident from the initial results of the study led by lung transplant specialist Erik Verschuuren and virologist Coretta van Leer of the UMCG.
Many of these patients still fear infection with the coronavirus on a daily basis, and many of them live in constant quarantine. They may benefit from a third or even fourth shot, but until then they are mostly dependent on vaccination coverage in their immediate environment and in society.
Patients who have had lung transplants are given medications to keep their bodies from rejecting the new lungs. These drugs suppress the immune system, but this also makes these patients more susceptible to viral infections, such as the coronavirus. The coronavirus is even more dangerous for them because the virus infects the transplanted organ, the lungs. In addition, an infection lasts longer because the immune response is suppressed.
A corona infection is a lot more dangerous for lung transplant patients than for healthy people. They have a greater chance of ending up in the ICU and of dying from corona.
Effect of the vaccine on kidney patients
In the Netherlands there are about 12,000 kidney transplant patients who use immunosuppressive drugs, about 60,000 patients with kidney failure and 6,000 dialysis patients. A research group led by internist-nephrologist Jan-Stephan Sanders of the UMCG is investigating the immune system response to a COVID-19 vaccination in these three patient groups.
The good news: the first results show that vaccination with a corona vaccine is safe for all kidney patients. Also good news: the first results show that the immune response in patients with kidney failure and dialysis patients is good: after two vaccinations they have produced sufficient antibodies. Whether this remains so needs further investigation. However, this does not apply to kidney transplant patients: 43% of this group have no antibodies.
Amount of antibodies
The researchers also looked at the amount of antibodies that people produce and to what extent they can inhibit the virus. Here too, kidney transplant patients do not score well: in 67% no or insufficient antibodies are produced. These are usually patients who have recently received a transplant, patients with lower kidney function, patients taking multiple immunosuppressive drugs, and patients taking immunosuppressive drugs containing the substance MMF.
Booster
A solution for these patients could be a booster: one or more extra vaccinations that would enable them to produce sufficient antibodies. The researchers are going to investigate effective applications of this. Perhaps it will help - if it is safe - to (temporarily) stop taking certain immunosuppressive drugs and then to vaccinate.
More information
More information about the study into the effects of the corona vaccine in people with cancer, the third study the UMCG is leading, will follow shortly. On the ZonMw website you can find all the information about the eight studies. You can also read their news item about the knowledge session here.
Lack of freedom underexposed
Because all the studies are structured in the same way, the researchers and ZonMw hope to eventually be able to draw comparisons between the various patient groups. What applies to all of them in any case is that they stand to benefit most from a high vaccination rate among people in their immediate vicinity and in society as a whole. Lung transplant specialist Erik Verschuuren: "Ultimately there will remain a large group of patients that we won't be able to protect against corona. In the discussion about the freedom that everyone in the Netherlands has to decide whether or not to be vaccinated, this remains underexposed. These patients are often desperate, and the freedom they are giving up is permanent.
https://www.umcg.nl/nl/w/nieuws/eer...oeken-werking-coronavaccins-kwetsbare-groepen
три броузери сменив, џабееееее. Оби вика во систем ваљда бројот ми е стар па затоа ме одбива.
